Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14392242 | 1.00 | PTPN1 (0.31) | PTPN1AKR1C3AKR1C2 | |
| SCHEMBL16602269 | 0.86 | KDM4C (0.32) | — | |
| SCHEMBL14392241 | 0.86 | KDM4E (0.36) | PTPN1 | |
| SCHEMBL10125912 | 0.86 | — | — | |
| SCHEMBL14367912 | 0.82 | KDM4C (0.34) | — | |
| SCHEMBL10110874 | 0.82 | KDM4C (0.31) | — | |
| SCHEMBL12518496 | 0.80 | KDM4C (0.40) | — | |
| SCHEMBL15004023 | 0.77 | KDM4C (0.37) | — | |
| SCHEMBL20647844 | 0.63 | — | — | |
| SCHEMBL458033 | 0.59 | CSNK2A1 (0.59) | PTPN1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9333232-B2 | Methods for treating papilloma virus infection | NANOVIR LLC (US) | 2016-05-10 | — | — | US | disclosed |
| US-9333232-B2 | Methods for treating papilloma virus infection | NANOVIR LLC (US) | 2016-05-10 | — | — | US | disclosed |
| US-9290551-B2 | Compounds for treating papilloma virus infection | NANOVIR LLC (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290551-B2 | Compounds for treating papilloma virus infection | NANOVIR LLC (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150239943-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2015-08-27 | — | — | US | disclosed |
| US-20150239943-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2015-08-27 | — | — | US | disclosed |
| US-8993609-B2 | Compounds for treating papilloma virus infection | NANOVIR, LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993609-B2 | Compounds for treating papilloma virus infection | NANOVIR, LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-20120225809-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | NANOVIR, LLC (US) | 2012-09-06 | — | — | US | disclosed |
| US-8119677-B2 | Polyamides containing amino butyric acid-based building blocks | NANOVIR, LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100015084-A1 | Compounds for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306164-A1 | Methods for Treating Papilloma Virus Infection | NANOVIR, LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-7589171-B2 | Polyamides for treating human papilloma virus | NANOVIR, LLC (US) | 2009-09-15 | — | — | US | disclosed |
| US-20070293417-A1 | Polyamides for treating human papilloma virus | NANOVIR, LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070293417-A1 | Polyamides for treating human papilloma virus | NANOVIR, LLC | 2007-12-20 | — | — | US | disclosed |
| WO-2007103584-A2 | POLYAMIDES FOR TREATING HUMAN PAPILLOMA VIRUS | NANOVIR, LLC (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225809-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | POLI, TLR3, PMAIP1 | PTPN1 3030/4885AKR1C3 1605/4885AKR1C2 2591/4885 |
| US-20090306164-A1 | Methods for Treating Papilloma Virus Infection | POLI, VHL, TLR3 | PTPN1 2404/4885AKR1C3 2245/4885AKR1C2 3166/4885 |
| US-20150239943-A1 | COMPOUNDS FOR TREATING PAPILLOMA VIRUS INFECTION | POLI, TLR3, PMAIP1 | PTPN1 3030/4885AKR1C3 1605/4885AKR1C2 2591/4885 |
| US-20100015084-A1 | Compounds for Treating Papilloma Virus Infection | POLI, PMAIP1, TLR3 | PTPN1 3170/4885AKR1C3 2187/4885AKR1C2 3046/4885 |
| US-20070293417-A1 | Polyamides for treating human papilloma virus | POLI, PARG, PARN | PTPN1 3669/4885AKR1C3 4062/4885AKR1C2 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.